-
Good Adherence to Anti-HIV Agents Seen in Children From Poorer Countries
Adherence to antiviral regimens among HIV-infected children in low-income countries is as good as - or better than - adherence by children in high-income countries.
Reuters Health Information, August 2008
-
Uninsured Rate Declines in US
A total of 45.7 million people are now without health insurance, a decrease of 15.3% as safety nets kick in.
WebMD Health News, August 2008
-
Effective Treatment of HIV in Children May Provoke Asthma
Immune reconstitution in HIV-infected children treated with highly active antiretroviral therapy (HAART) appears to increase their risk of developing asthma, according to data from the prospective Women and Infants Transmission Study.
Reuters Health Information, August 2008
-
Study Supports Prompt HCV Therapy in HIV/HCV-Coinfected Patients
Patients coinfected with hepatitis C virus (HCV) and HIV often exhibit low levels of HCV neutralizing antibodies, which could contribute to a poorer outcome of HCV infection, a French study indicates.
Reuters Health Information, August 2008
-
Pegylated Liposomal Doxorubicin Prevents Relapse of HIV-Related Kaposi Sarcoma
Among HIV-infected patients treated with pegylated liposomal doxorubicin for Kaposi sarcoma (KS), relapse rates are low, according to a report in the August 1st issue of Clinical Infectious Diseases.
Reuters Health Information, August 2008
-
Maternal Screening for Down Syndrome Accurate in HIV-Infected Women
Maternal biochemical serum screening for Down syndrome in pregnancy is accurate in HIV-infected women, according to a report in the August Obstetrics & Gynecology.
Reuters Health Information, August 2008
-
HAART Improves Syphilis Serologic Response Rates in HIV Patients
Highly active antiretroviral therapy (HAART) reduces syphilis serological failure rates in patients co-infected with HIV, according to researchers at Johns Hopkins University School of Medicine.
Reuters Health Information, August 2008
-
Switching to Second-Line ART Infrequent in MSF's HIV Programs
Few of the more than 48,000 patients being treated for HIV in Medecins San Frontieres (MSF) programs in resource-limited settings have required changing to second-line antiretroviral (ART) therapy, according to French and Swiss researchers.
Reuters Health Information, August 2008
-
Fibrotic Damage by HIV Limits Immune Reconstitution in Lymphatic Tissues in Gut
Early in the course of HIV infection, collagen deposition in gut-associated lymphatic tissues (GALT) causes greater CD4+ T cell depletion than in other lymph tissues and limits the extent of immune reconstitution that can be achieved with antiretroviral medications, according to research by scientists at the University of Minnesota in Minneapolis and at the National Institutes of Health in Bethesda, Maryland.
Reuters Health Information, August 2008
-
Fighting Domestic Violence May Help Stem Global HIV Epidemic
Public-health efforts to prevent domestic abuse in women may aid in the global fight against HIV infection, new research suggests.
Medscape Medical News, August 2008
-
Lopinavir/ritonavir May Curb Lipoatrophy in HIV
Limb fat loss is less frequent in patients with HIV who receive lopinavir/ritonavir (Kaletra) therapy compared to efavirenz plus zidovudine/lamivudine, according to North American and Spanish researchers.
Reuters Health Information, August 2008
-
Abacavir May Be Less Effective in HIV Patients With High Viral Load
In the ACTG 5202 trial, abacavir may have lead to a higher rate of virologic failure in patients with a high viral load, although a separate company-supported trial shows a different view.
Medscape Medical News, August 2008
-
Minority HIV-1 Drug Resistance Mutations Present in Untreated HIV-Infected Patients
In treatment-naive HIV-infected patients, a small percentage of viruses may harbor resistance mutations that are undetected by conventional genotyping. However, these minority HIV resistance mutations are associated with reduced treatment efficacy, according to a report in the July issue of PLoS Medicine.
Reuters Health Information, August 2008
-
Viral Suppression Achievable With Four-Drug Therapy in HIV-Infected African Infants
Infants with perinatal HIV infection despite single-dose nevirapine therapy respond well to a four-drug/three-class antiretroviral treatment regimen, according to a feasibility study conducted in South Africa.
Reuters Health Information, August 2008
-
Abacavir May Increase Risk for CVD in Subset of Patients
In an analysis of the SMART trial, long-term use of abacavir was associated with increased cardiovascular disease risk and higher levels of IL-6 and hs-CRP in a subset of patients. However, a company-funded study found the opposite.
Medscape Medical News, August 2008
-
Antiretrovirals: No Increased Risk of Atherosclerosis
Antiretroviral drugs for HIV infection do not increase the risk of coronary atherosclerosis, a new study has found. The results should reassure doctors who have been concerned about this, say the researchers.
Heartwire, August 2008
-
Combination Strategy Promising for HIV Vaccination
In vitro studies indicate that a trimolecular vaccination approach using HIV-1-specific and non-cognate immune responses is potentially more effective in producing neutralizing antibody activity than is a single antigen, UK researchers report in the July 11th issue of AIDS.
Reuters Health Information, August 2008
-
Polymorphisms in HIV-1 Gag Are Associated With Plasma Viral Load
In chronic untreated HIV infection, the total number of HLA-associated polymorphisms in the viral gene encoding the Gag protein is inversely associated with plasma viral load, according to a report in the July 11th issue of AIDS.
Reuters Health Information, August 2008
-
TRIO of New HIV Drugs Leads to Undetectable Viral Load in 90% of Treatment-Experienced Patients
Three recently approved drugs, when used in combination and with optimized background therapy, offer outstanding suppression of viral load.
Medscape Medical News, August 2008
-
Progress Made on 3 Second-Generation NNRTIs
New second-generation nonnucleoside reverse transcriptase inhibitors, some of which show activity against HIV strains resistant to current first-line therapy, continue to show promise.
Medscape Medical News, August 2008
